Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis (SCALA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02583594
Recruitment Status : Active, not recruiting
First Posted : October 22, 2015
Last Update Posted : October 24, 2018
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )

Brief Summary:

Primary Objective:

  • To characterize the pharmacodynamic profile of 2 treatment courses of alemtuzumab administered by subcutaneous injection and 2 treatment courses of alemtuzumab administered by intravenous infusion in patients with progressive multiple sclerosis.

Secondary Objectives:

  • To characterize the pharmacokinetic profiles of alemtuzumab administered by subcutaneous injection or intravenous infusion to patients with progressive multiple sclerosis.
  • To characterize the safety and tolerability of alemtuzumab administered by subcutaneous injection or intravenous infusion to patients with progressive multiple sclerosis.

Condition or disease Intervention/treatment Phase
Progressive Multiple Sclerosis Drug: Acyclovir Drug: Methylprednisolone Drug: alemtuzumab GZ402673 Drug: Paracetamol Drug: Loratadine Drug: Ceterizine Drug: Dexchlorpheniramine Phase 1

Detailed Description:
The duration of study per patient will be approximately 61 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis
Study Start Date : December 6, 2015
Actual Primary Completion Date : March 2016
Estimated Study Completion Date : April 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Alemtuzumab

Arm Intervention/treatment
Experimental: alemtuzumab (subcutaneous injection)
Dose 1 (initial course) of alemtuzumab will be administered subcutaneously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
Drug: Acyclovir
Pharmaceutical form:tablet Route of administration: oral

Drug: Methylprednisolone
Pharmaceutical form:tablet Route of administration: oral

Drug: alemtuzumab GZ402673
Pharmaceutical form:injection Route of administration: subcutaneous

Drug: Paracetamol
Pharmaceutical form:tablet Route of administration: oral

Drug: Loratadine
Pharmaceutical form:tablet Route of administration: oral

Drug: Ceterizine
Pharmaceutical form:tablet Route of administration: oral

Drug: Dexchlorpheniramine
Pharmaceutical form:tablet Route of administration: oral

Experimental: alemtuzumab (intravenous infusion)
Dose 1 (initial course) of alemtuzumab will be administered intravenously on 5 consecutive days, followed by Dose 2 (second course) on 3 consecutive days administered 12 months after initial course. Pre-medications (methylprednisolone, antihistamine [loratadine, cetirizine, dexchlorpheniramine], paracetamol, acyclovir) will be administered prior alemtuzumab administration.
Drug: Acyclovir
Pharmaceutical form:tablet Route of administration: oral

Drug: Methylprednisolone
Pharmaceutical form:tablet Route of administration: oral

Drug: alemtuzumab GZ402673
Pharmaceutical form:solution for infusion Route of administration: intravenous

Drug: Paracetamol
Pharmaceutical form:tablet Route of administration: oral

Drug: Loratadine
Pharmaceutical form:tablet Route of administration: oral

Drug: Ceterizine
Pharmaceutical form:tablet Route of administration: oral

Drug: Dexchlorpheniramine
Pharmaceutical form:tablet Route of administration: oral




Primary Outcome Measures :
  1. Change from baseline in the CD3+ lymphocyte subset after alemtuzumab administration [ Time Frame: Baseline, 30 days after each treatment course ]

Secondary Outcome Measures :
  1. Change from baseline in lymphocyte subsets after alemtuzumab administration [ Time Frame: Baseline, 30 days after each treatment course ]
  2. Change from baseline in total lymphocyte count after alemtuzumab administration [ Time Frame: Baseline, 30 days after each treatment course ]
  3. Change from baseline in helper/suppressor ratio after alemtuzumab administration [ Time Frame: Baseline, 30 days after each treatment course ]
  4. Assessment of pharmacokinetic parameter after alemtuzumab administration: maximum plasma concentration observed (Cmax) [ Time Frame: 30 days after each treatment course ]
  5. Assessment of pharmacokinetic parameter after alemtuzumab administration: time to reach Cmax (Tmax) [ Time Frame: 30 days after each treatment course ]
  6. Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration versus time curve from time zero until the last measurable concentration (AUClast) [ Time Frame: 30 days after each treatment course ]
  7. Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration (AUC) [ Time Frame: 30 days after each treatment course ]
  8. Assessment of pharmacokinetic parameter after alemtuzumab administration: terminal half-life (t1/2z) [ Time Frame: 30 days after each treatment course ]
  9. Number of patients with adverse events [ Time Frame: 4 years ]
  10. Number of patients with adverse events of special interest [ Time Frame: 4 years ]
  11. Number of patients with injection site reactions [ Time Frame: 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Male or female adults with a diagnosis of Multiple Sclerosis (MS) based on 2010 revision of McDonald criteria.
  • Diagnosis of progressive MS including primary progressive MS and secondary progressive MS.
  • Age ≥18 years.
  • Signed informed consent form.
  • Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.
  • Not under any administrative or legal supervision.

Exclusion criteria:

  • Patients with relapsing remitting MS.
  • Any prior treatment with alemtuzumab or other anti-CD52 antibodies.
  • Treatment with natalizumab in the 4 months prior to Study Visit 1.
  • Progressive multifocal leukoencephalopathy (PML), or any clinical or imaging signs possibly indicative of undiagnosed PML. Particular vigilance is needed for patients with prior natalizumab exposure, even if the last exposure was more than 4 months prior to Study Visit 1.
  • Treatment with methotrexate, azathioprine, or cyclosporine in the past 6 months.
  • Treatment with mitoxantrone, cyclophosphamide, cladribine, rituximab, or any other immunosuppressant or cytotoxic therapy (other than steroids) in the last 12 months, or determined by the treating physician to have residual immune suppression from these treatments.
  • Treatment with glatiramer acetate or interferon beta in the past 4 weeks.
  • Treatment with fingolimod within the past 2 months.
  • Treatment with dimethyl fumarate in the past 4 weeks.
  • Treatment with teriflunomide within the past 12 months unless the patient has completed an accelerated clearance with cholestyramine or activated charcoal.
  • Any known contraindications to the symptomatic therapy used in the infusion management guidance for this study.
  • Hypersensitivity or contraindication to acyclovir.
  • History of a hypersensitivity reaction other than localized injection site reaction to any biological molecule.
  • If female, pregnancy (defined as positive β-HCG blood test) or lactating or breast-feeding.
  • Current participation in another investigational interventional study.
  • Any significant change in chronic treatment medication (ie, new chronic medication) within 14 days before inclusion.
  • An investigational medicinal product within 3 months or 5 half-lives, whichever is longer, before study inclusion.
  • Total lymphocyte or CD3+ counts are below normal limits at screening. If abnormal cell count(s) return to within normal limits, eligibility may be reassessed.
  • Live, attenuated vaccine within 3 months prior to the randomization (Day 1) visit, such as varicella-zoster, oral polio, rubella vaccines.
  • Any clinically relevant findings in the physical examination, medical history, or laboratory assessments which would compromise the safety of the patient.
  • Women of childbearing potential not protected by highly-effective method(s) of birth control and/or who are unwilling or unable to be tested for pregnancy.
  • Latent or active tuberculosis infection, verified by testing as per local practice.
  • Infection with human immunodeficiency virus (HIV).
  • Known Hepatitis B (HBV) or Hepatitis C (HCV) infection.
  • Active infection, eg, deep tissue infection, that the Investigator considers sufficiently serious to preclude study participation.
  • Prior history of invasive fungal infections.
  • Any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a language problem or poor mental development.
  • Any patient in the exclusion period of a previous study according to applicable regulations.
  • Any patient who cannot be contacted in case of emergency.
  • Any patient who is the Investigator or any subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02583594


Locations
Layout table for location information
Spain
Investigational Site Number 724001
Barcelona, Spain, 08035
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi

Layout table for additonal information
Responsible Party: Genzyme, a Sanofi Company
ClinicalTrials.gov Identifier: NCT02583594    
Other Study ID Numbers: TDU14260
2015-002550-12 ( EudraCT Number )
U1111-1171-7939 ( Other Identifier: UTN )
First Posted: October 22, 2015    Key Record Dates
Last Update Posted: October 24, 2018
Last Verified: October 2018
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Acetaminophen
Loratadine
Chlorpheniramine
Acyclovir
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Alemtuzumab
Prednisolone hemisuccinate
Prednisolone phosphate
Dexchlorpheniramine
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Anti-Inflammatory Agents
Antiemetics